Vitality Watch

Dossier pubmed preclinical 29-aug-2026
Animal model, organoid, or cell-culture result — not yet human

NADprecursor treatment prevents cardiomyopathy but disrupts erythroid maturation in mitochondrial progeria.

Key claim: Chronic nicotinamide riboside prevents cardiomyopathy in mitochondrial progeria mutator mice but causes reductive stress in bone marrow that disrupts erythroid maturation and worsens anemia.

Abstract

Nicotinamide adenine dinucleotide (NAD) plays a central role in energy metabolism, and its decline is linked to various degenerative diseases. While NADrestoration holds therapeutic promise, its long term, tissue-specific consequences remain poorly understood. We investigated effects of nicotinamide riboside (NR) supplementation for “mutator” mice manifesting mitochondrial progeria. Our results reveal strikingly divergent outcomes: in proliferative bone marrow, NR-treated mutators show reductive stress with accumulation of NADH/NADPH, altered amino acid, nucleotide, folate levels, and impaired heme biosynthesis. In blood, erythrocyte maturation defects are aggravated, exacerbating anemia. Conversely, in postmitotic cardiac tissue, NR enhanced contractility, reduces stress response markers and normalized metabolic profile. These findings indicate that while beneficial for heart, chronic NADboosting can compromise erythrocyte maturation in the context of mitochondrial disease. The data emphasize importance of evaluating systemic effects of NADboosting therapies beyond the primary affected tissues and development of tissue-specific metabolic interventions for degenerative diseases.

Why this matters

NAD-precursor supplementation has been pitched as a broadly geroprotective mitochondrial-rescue strategy, but this mutator-mouse study shows the same chronic NR dose that protects the aged heart drives bone marrow into reductive stress and worsens anemia. It concretizes the emerging reductive-stress caveat around NAD boosters — the intervention is not tissue-neutral, and proliferative compartments with high biosynthetic demand may pay a cost the postmitotic heart does not.

Source

Link

Briefing card

NADprecursor treatment prevents cardiomyopathy but disrupts erythroid maturation in mitochondrial progeria.
Stage: preclinical · pubmed · 29-aug-2026

If you take NR chronically, this mouse study found opposite effects across tissues — cardiac protection alongside disrupted red blood cell maturation from bone-marrow reductive stress.

Chronic nicotinamide riboside prevents cardiomyopathy in mitochondrial progeria mutator mice but causes reductive stress in bone marrow that disrupts erythroid maturation and worsens anemia.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.celrep.2026.117849

build build 880 · 2bcef25 · 2026-11-18